ABSTRACT
The glycoprotein IIb-IIIa inhibitors are extremely effective antiplatelet drugs. However their efficacy is tainted by their prohibitive cost. The objective of this work is the evaluation of the use of the glycoprotein IIb-IIIa inhibitors in the coronary angioplasty in terms of indication, patients profile and tolerance. Among the 51 patients included in the study 72,5% were treated with tirofiban; whereas 27,5% received abciximab. The glycoprotein IIb-IIIa inhibitors were respectively used in 19,6%, 43,1%, 35,3%, and 2% of the cases in the acute coronary syndromes with ST segment elevation, in the interventionnelle cardiology and the intra stent restenosis. In term of vigilance, only one major hemorrhagic accident was detected. A rigorous follow-up of the biological parameters of the patients makes it possible however to deal with this effect quickly. The introduction of a new therapeutic class, as expensive as, of antiplatelet drugs into a hospital must be the object of clinical evaluation. Finally, this study must be exercised, in particular within the framework of the pharmacovigilance